Ehlers-Danlos syndrome video series: how a multidisciplinary team helped improve patient outcomes
This series of videos are about a rare condition called Ehlers-Danlos syndrome, and how working as a multidisciplinary team can improve patient outcomes. The videos include interviews with a consumer, Tracey, and members of the multidisciplinary team that help to manage her condition.
The prolotherapy treatment described within these videos is provided using Food and Drug Administration (FDA) approved sole sclerosing agents off-label, combined with manipulation. This treatment is funded by Medicare in Australia, ACC in New Zealand and within the New Zealand district health board system via Pharmac.
Prolotherapy using agents such as dextrose is not currently publicly funded within New Zealand but there are studies showing benefit. Download a copy of the opinion (660KB, pdf), written by Dr David Rabago from Penn State College of Medicine.
Read more about Tracey and development of these videos: Multidisciplinary team improves care for consumer with rare condition.
Consumer story: Living with Ehlers-Danlos syndrome
Download a copy of the accessible transcript (29KB, docx)
Managing Ehlers-Danlos syndrome: a physician's perspective
Download a copy of the accessible transcript (32KB, docx)
Managing Ehlers-Danlos syndrome: a physiotherapist's perspective
Download a copy of the accessible transcript (29KB, docx)
Managing Ehlers-Danlos syndrome: an osteopath's perspective
Download a copy of the accessible transcript (28KB, docx)
Managing Ehlers-Danlos syndrome: panel discussion part 1
Download a copy of the accessible transcript (33KB, docx)
Managing Ehlers-Danlos syndrome: panel discussion part 2
Download a copy of the accessible transcript (30KB, docx)
The prolotherapy treatment described within these videos is provided using Food and Drug Administration (FDA) approved sole sclerosing agents off-label, combined with manipulation. This treatment is funded by Medicare in Australia, ACC in New Zealand and within the New Zealand district health board system via Pharmac.
Prolotherapy using agents such as dextrose is not currently publicly funded within New Zealand but there are studies showing benefit.
